Geron’s Huge Deal with J&J

Home/Financial/Geron’s Huge Deal with J&J

Geron’s Huge Deal with J&J

Coverage of Geron’s recent big deal with Johnson & Johnson:

  • “Geron Corp. will hand over its experimental blood cancer drug imetelstat to Johnson & Johnson’s Janssen Biotech Inc. unit for $35 million upfront, the Menlo Park company said Thursday. The deal ultimately could be worth $900 million if certain development, regulatory and commercial milestones are hit over several years.” – Ron Leuty, SF Business Times More

  • “Geron Corp.’s savior has arrived, with Janssen Biotech Inc. pledging $35 million up front plus $900 million in potential milestone payments for an exclusive license to the company’s sole pipeline asset, imetelstat. The deal inaugurates what Geron CEO Chip Scarlett called “a new chapter” for the Menlo Park, Calif.-based company, opening the door for possible additions to its pipeline, while fully covering the costs of imetelstat’s development in up to three hematologic cancers and reviving the value of its shares, which rose to 19.5 percent to $2.76 Friday from Thursday’s $2.31 close, just a dollar above a 52-week low. (See BioWorld Today, March 13, 2014.)” – Michael Fitzhugh, BioWorld More

  • “For Geron, the deal is hardly a golden ticket, and, with the companies agreeing to split R&D costs 50-50, the biotech will be using a fair bit of that new cash just to keep imetelstat moving. But, in J&J, the company has found a partner with a pedigree for making the best of such collaborations. J&J’s external R&D team is responsible for wooing Pharmacyclics  and getting its blood cancer treatment ibrutinib all the way to FDA approval. And analysts have hailed similar promise for daratumumab, a multiple myeloma treatment J&J licensed from Genmab for up to $1.1 billion, and ARN-509, the prostate cancer-fighting star of the company’s $1 billion deal for Aragon.” – Damian Garde, FierceBiotech More

  • “Based in Menlo Park, CA, the former developer of a cutting-edge stem-cell therapy decided three years ago to ditch stem cells, even though it had managed to start a landmark study in people with spinal cord injuries, and instead pursue a more conventional biotech line: modified nucleic acids to treat cancer. Since the switch, Geron has devoted most of its attention to developing its main product, imetelstat, in blood disorders.” – Alex Lash, Xconomy More
November 17th, 2014|
X